WO1999011778B1 - Traitement antisense de l'hypertension pulmonaire - Google Patents
Traitement antisense de l'hypertension pulmonaireInfo
- Publication number
- WO1999011778B1 WO1999011778B1 PCT/GB1998/002584 GB9802584W WO9911778B1 WO 1999011778 B1 WO1999011778 B1 WO 1999011778B1 GB 9802584 W GB9802584 W GB 9802584W WO 9911778 B1 WO9911778 B1 WO 9911778B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapeutic composition
- inhaler
- seq
- composition according
- oligonucleotide
- Prior art date
Links
- 230000000692 anti-sense effect Effects 0.000 title claims abstract 6
- 208000002815 pulmonary hypertension Diseases 0.000 title claims abstract 5
- 238000000034 method Methods 0.000 claims abstract 3
- 210000004072 lung Anatomy 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims 21
- 230000001225 therapeutic effect Effects 0.000 claims 17
- 108091034117 Oligonucleotide Proteins 0.000 claims 7
- 101800004490 Endothelin-1 Proteins 0.000 claims 6
- 108091033380 Coding strand Proteins 0.000 claims 2
- 102400000686 Endothelin-1 Human genes 0.000 claims 2
- 238000002844 melting Methods 0.000 claims 2
- 230000008018 melting Effects 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 108700024394 Exon Proteins 0.000 claims 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims 1
- 108091092195 Intron Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU88741/98A AU8874198A (en) | 1997-09-02 | 1998-09-02 | Antisense treatment of pulmonary hypertension |
CA002302167A CA2302167A1 (fr) | 1997-09-02 | 1998-09-02 | Traitement antisense de l'hypertension pulmonaire |
JP2000508789A JP2001515011A (ja) | 1997-09-02 | 1998-09-02 | 肺高血圧症のアンチセンス治療 |
EP98940410A EP1009822A1 (fr) | 1997-09-02 | 1998-09-02 | Traitement antisense de l'hypertension pulmonaire |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9718487.3 | 1997-09-02 | ||
GBGB9718487.3A GB9718487D0 (en) | 1997-09-02 | 1997-09-02 | Pulmonary hypertension |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999011778A1 WO1999011778A1 (fr) | 1999-03-11 |
WO1999011778B1 true WO1999011778B1 (fr) | 1999-04-15 |
Family
ID=10818333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1998/002584 WO1999011778A1 (fr) | 1997-09-02 | 1998-09-02 | Traitement antisense de l'hypertension pulmonaire |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1009822A1 (fr) |
JP (1) | JP2001515011A (fr) |
AU (1) | AU8874198A (fr) |
CA (1) | CA2302167A1 (fr) |
GB (1) | GB9718487D0 (fr) |
WO (1) | WO1999011778A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1086116A4 (fr) * | 1998-05-21 | 2004-03-17 | Isis Pharmaceuticals Inc | Compositions destinees a l'administration pulmonaire d'acides nucleiques et procedes |
JP2002515513A (ja) * | 1998-05-21 | 2002-05-28 | アイシス・ファーマシューティカルス・インコーポレーテッド | 核酸の肺送達のための組成物および方法 |
US6087343A (en) * | 1998-09-14 | 2000-07-11 | University Of Florida | Antisense oligonucleotides targeted to β-1 adrenoceptor and methods of use |
WO2000055314A2 (fr) * | 1999-03-18 | 2000-09-21 | United Therapeutics Corporation | Inhibiteurs de synthese de l'endotheline-1 |
AU2001289861A1 (en) * | 2000-09-19 | 2002-04-02 | Epidauros Biotechnologie Ag | Polymorphisms in human genes of cardiovascular regulators and their use in diagnostic and therapeutic applications |
WO2016083624A1 (fr) * | 2014-11-28 | 2016-06-02 | Silence Therapeutics Gmbh | Moyens d'inhibition de l'expression d'edn1 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2279014B (en) * | 1993-06-02 | 1997-07-16 | Niall Keaney | Device for controlling delivery of respiratory drugs |
GB9320978D0 (en) * | 1993-10-12 | 1993-12-01 | Higenbottam Timohy W | Nitric oxide treatment |
US5994315A (en) * | 1995-06-07 | 1999-11-30 | East Carolina University | Low adenosine agent, composition, kit and method for treatment of airway disease |
GB2320900B (en) * | 1997-01-07 | 2000-08-30 | Univ Sheffield | Inhalers |
-
1997
- 1997-09-02 GB GBGB9718487.3A patent/GB9718487D0/en not_active Ceased
-
1998
- 1998-09-02 EP EP98940410A patent/EP1009822A1/fr not_active Withdrawn
- 1998-09-02 CA CA002302167A patent/CA2302167A1/fr not_active Abandoned
- 1998-09-02 WO PCT/GB1998/002584 patent/WO1999011778A1/fr not_active Application Discontinuation
- 1998-09-02 JP JP2000508789A patent/JP2001515011A/ja active Pending
- 1998-09-02 AU AU88741/98A patent/AU8874198A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1999011778A1 (fr) | 1999-03-11 |
JP2001515011A (ja) | 2001-09-18 |
EP1009822A1 (fr) | 2000-06-21 |
CA2302167A1 (fr) | 1999-03-11 |
GB9718487D0 (en) | 1997-11-05 |
AU8874198A (en) | 1999-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU745324B2 (en) | Therapeutic methods comprising use of a neuregulin | |
Sato et al. | Anticonvulsant action of a non-competitive antagonist of NMDA receptors (MK-801) in the kindling model of epilepsy | |
Gordon et al. | Enhancement of morphine analgesia by the GABAB agonist baclofen | |
AU727851B2 (en) | Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors | |
Glazner et al. | Elevated insulin-like growth factor (IGF) gene expression in sciatic nerves during IGF-supported nerve regeneration | |
Liu et al. | Neuroprotective effect of chronic infusion of basic fibroblast growth factor on seizure-associated hippocampal damage | |
JP2006502100A (ja) | 細胞の異常消失に関わる障害の治療のための、および/または、肥満の治療のためのgip活性を有する化合物の使用 | |
JP2010535508A5 (fr) | ||
AU2527800A (en) | Methods to enhance white blood cell count | |
Francis Pau et al. | Hypothalamic site‐dependent effects of neuropeptide Y on gonadotropin‐releasing hormone secretion in rhesus macaques | |
CN1582146A (zh) | 用非多肽环-磷酸腺苷水平调节剂诱导排卵的方法 | |
WO1999011778B1 (fr) | Traitement antisense de l'hypertension pulmonaire | |
WO2000033814A2 (fr) | Technique d'apport d'agents au systeme nerveux central | |
Wilson 3rd et al. | Prolactin message in brain and pituitary of adult male rats is identical: PCR cloning and sequencing of hypothalamic prolactin cDNA from intact and hypophysectomized adult male rats | |
CA2456223A1 (fr) | Regulation du recepteur apj permettant le traitement ou la prevention de maladies cardiaques | |
Hanaoka et al. | Effect of 4-methylcatechol on sciatic nerve growth factor level and motor nerve conduction velocity in experimental diabetic neuropathic process in rats | |
WO2005033282A2 (fr) | Compositions polyamide et methodes therapeutiques pour traiter un papillomavirus humain | |
RU2003134949A (ru) | Способ лечения деменции и нейродегенеративных заболеваний и применение в нем качестве лекарственного средства промежуточных доз антагонистов lhrh | |
AU2002310788A1 (en) | Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists | |
Hefti et al. | Protective effects of nerve growth factor and brain-derived neurotrophic factor on basal forebrain cholinergic neurons in adult rats with partial fimbrial transections | |
US9668995B2 (en) | Treatment of motor fluctuations | |
AU782357B2 (en) | Treatment of dyskinesia | |
WO2007139433A8 (fr) | Substance peptidique normalisant le métabolisme dans les tissus osseux et cartilagineux, composition pharmaceutique à base de ladite substance et procédé d'application afférent | |
JPH06321774A (ja) | 全身麻酔薬とセレギリンを含有する麻酔薬組成物 | |
EP0813873A1 (fr) | Compositions pharmaceutiques comprenants de la mirtazapine et un ou plusieurs inhibiteurs sélectifs d'assimilation de sérotonine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998940410 Country of ref document: EP |
|
ENP | Entry into the national phase in: |
Ref document number: 2302167 Country of ref document: CA Ref country code: CA Ref document number: 2302167 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase in: |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09486815 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998940410 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998940410 Country of ref document: EP |